Table 8.

Overall survival based on subtype and systemic therapies

	3-year OS (%)	5-year OS (%)	6-year OS (%)	7-year OS (%)
Luminal A (n = 2102)
ET (n = 1291, 61.4 %) → 97 events	96.7	92.3	90.8	88.3
CHT + ET (n = 489, 23.3 %) → 28 events	98.7	97.1	96.2	95.1
CHT (n = 52, 2.5 %) → 5 events	94.2	90.5	86.2	86.2
Other (n = 270, 12.8 %) → 54 events	82.8	76.1	70.3	61.5
Luminal B (n = 1078)
ET (n = 454, 42.1 %) → 80 events	93.4	85.8	81.9	78.7
CHT + ET (n = 440, 40.8 %) → 43 events	97.3	92.9	90.9	89.4
CHT (n = 56, 5.2 %) → 9 events	89.9	82.9	78.3	78.3
Other (n = 128, 11.9 %) → 44 events	71.7	61.2	51.9	46.8
HER2-like (n = 774)
ET + Trastuzumab (n = 13, 1.7 %) → 0 events	100	100	100	100
ET (n = 157, 20.3 %) → 26 events	93.3	88.2	82.1	82.1
CHT + ET (n = 113, 14.6 %) → 14 events	98.2	95.1	89.7	88.6
CHT + ET + Trastuzumab (n = 193, 24.9 %) → 7 events	97.5	95.4	95.4	93.3
CHT + Trastuzumab (n = 107, 13.8 %) → 8 events	96.1	94.6	90.7	87.2
CHT (n = 73, 9.4 %) → 21 events	80.1	71.7	71.7	71.7
Other (n = 118, 15.2 %) → 43 events	71.9	57.3	48.8	46.5
Basal-like (n = 390)
ET (n = 3, 0.8 %) → 0 events	–	–	–	–
CHT + ET (n = 13, 3.3 %) → 1 event	92.3	92.3	92.3	92.3
CHT + Trastuzumab (n = 2, 0.5 %) → 1 event	100	50	–	–
CHT (n = 270, 69.2 %) → 34 events	90.7	86.5	86.5	85.6
Other (n = 102, 26.2 %) → 33 events	67.6	65.9	65.9	59.9